| Drug Name |
Olanzapine pamoate |
| Drug ID |
BADD_D01600 |
| Description |
Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent.[A176996] The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions.[A177011] Olanzapine very closely resembles [clozapine] and only differs by two additional methyl groups and the absence of a chloride moiety.[T554] It was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996.[T548] |
| Indications and Usage |
For the acute and maintenance treatment of schizophrenia and related psychotic disorders, as well as acute treatment of manic or mixed episodes of bipolar 1 disorder. Intramuscular olanzapine is indicated for the rapid control of agitated patients. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
N05AH03 |
| DrugBank ID |
DB00334
|
| KEGG ID |
D06623
|
| MeSH ID |
D000077152
|
| PubChem ID |
135566032
|
| TTD Drug ID |
D0V4QS
|
| NDC Product Code |
71161-143; 0002-2344; 0002-7637; 0002-2003; 71161-144; 0002-7635; 71161-142; 0002-7636; 0002-1606 |
| Synonyms |
Olanzapine | 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine | LY-170052 | LY 170052 | LY170052 | Zyprexa | Zolafren | LY 170053 | Olanzapine Pamoate |
